The gene for multiple endocrine neoplasia type 1 (MENi), an inherited predisposition to neuroendocrine neoplasm of the parathyroid glands, the pancreatic islet parenchyma, and the anterior pituitary gland, was recently mapped to chromosome 11q13 based on genetic linkage in families. We now show that the pathogenesis of MEN1-associated parathyroid lesions involves unmaking of a recessive mutation at the disease locus and that sporadic primary hyperparathyroidism shares the same mechanisms. MENi patients and from 24 patients with sporadic primary hyperparathyroidism were fresh-frozen and stored at -700C.
Multiple endocrine neoplasia type 1 (MEN1) is a genetic disorder that consists of neoplasia of neuroendocrine type in the parathyroid glands, in the islets of Langerhans in the pancreas, and in the anterior lobe of the pituitary gland (1, 2) . Larsson et al. (3) mapped the MENi-susceptibility locus (MEN)) to chromosome 11q13 by genetic linkage to restriction fragment length polymorphism (RFLP) markers in families segregating the disease. By identifying meiotic crossovers in MEN1 families, Nakamura et al. (4) determined that the disease gene was within a region extending 5 centimorgans (cM) on either side of the PYGM locus, flanked by the DIIS288 locus on the centromeric side and by INT2 on the telomeric side. Furthermore, comparisons of the genotypes in normal and tumor tissue from the same individual showed that the pathogenesis of insulinoma as well as premalignant pancreatic hyperplasia involved unmasking of a recessive mutation at the MEN) locus (3) , in agreement with the two-mutation model originally postulated by Knudson (5) .
This mechanism was first outlined in detail for retinoblastoma (RB) and osteosarcoma, associated with the heritable form of this disease (6) (7) (8) . In these, tumorigenesis involves two mutational events. Individuals genetically predisposed to RB carry a constitutional mutation of the RB gene on chromosome 13 in heterozygous form, whereas in sporadic cases the first mutation is somatic. Tumors arise if a second mutational event, usually a gross chromosome 13 deletion, eliminates the remaining wild-type allele (6, 7) . Furthermore, tumors show no expression or an abnormal transcript of the RB gene (9) (10) (11) (12) , and in vitro introduction of a normal gene into such cells resulting in RB gene expression may revert the malignant phenotype (13 Tables 1 and 2 . Surgically obtained parathyroid glands extirpated because of primary hyperparathyroidism from 5 MENi patients and from 24 patients with sporadic primary hyperparathyroidism were fresh-frozen and stored at -700C.
The parathyroid lesions 11-3 LU-HPT and HPT-EZ were obtained from members of the LU and EZ kindreds (3). Specimens of insulinoma parenchyma from case II-1 of the LU kindred (3) were also included.
Pituitary tumors from 27 cases, all but one (APA-23) with no signs of MEN1, were obtained by a trans-sphenoidal surgical approach and treated in the same manner. Four patients had Cushing disease due to adrenocorticotropinproducing adenomas, 10 patients suffered from acromegaly due to growth hormone-producing pituitary adenomas, 3 patients had prolactinomas, nine patients harbored nonsecreting adenomas, and 1 had a thyrotropin-producing pituitary adenoma ( (14) . The chromosome 11 loci studied are shown in Fig. 1 IlTo whom reprint requests should be addressed.
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In all but 2 cases, every informative marker on chromosome 11 showed loss of one constitutional allele, which is consistent with loss of one chromosome 11 complement in the tumor parenchyma. Patient 11-3 of the LU kindred had inherited MENi from his mother, and the haplotype of the maternal chromosome 11 was determined by family analysis (3) . At every informative locus, the parathyroid tumor showed loss of the allele derived from the unaffected father, while the maternal chromosome 11 complement was retained. Furthermore, genotype examination of insulinoma and pancreatic hyperplasia tissue from this patient showed loss of the same alleles as in the parathyroid lesion (3) . These observations confirm the hypothesis that MENi-associated parathyroid lesions involve unmasking of a recessive mutation at the MEN] locus and that the pathogenesis of sporadic parathyroid lesions involves loss of a normal balancing allele at the MEN] locus.
Constitutional and tumor genotypes were examined for markers on eight other chromosomes, numbers 1, 2, 4, 5, 10, 13, 17, and 22. As shown in Table 1 , allele losses on chromosomes other than chromosome 11 were observed in only four cases, i.e., on chromosomes 1 and 4 in HPT-8, chromosome 1 in HPT-21, and chromosome 22 in HPT-9 and HPT-11. HPT-8 and HPT-21 retained constitutional genotypes on chromosome 11, whereas chromosome 11 was affected in HPT-9 and HPT-11.
Loss of Alleles in Anterior Pituitary Adenomas. Constitutional and tumor genotypes were compared in 1 MEN1-associated and 26 sporadic pituitary adenomas. As shown in Table 2 , loss of alleles was observed in 5 tumors. However, only 2 cases (APA-29 and APA41) showed loss of alleles for markers on chromosome 11. For both these cases the allele losses were partial in the sense that the signal intensity was reduced by -5WO for one allele at all informative loci on chromosome 11 (data not shown). This is consistent with loss of chromosome 11 alleles in only part of these tumors, either because the parenchyma contained a mixture of normal and adenoma cells or alternatively, because these allele losses were restricted to a subclone of the neoplastic cells, thus representing a secondary event in tumorigenesis. APA-41 showed a reduced signal intensity of one allele for the PYGM and DI IS146 loci, indicating loss of one allele at the MEN) locus. In this adenoma the constitutional genotype was retained for markers on chromosomes 1, 2, 10, and 13. APA-29 showed reduced signal intensities for one allele ofthe PTH and DJJS12 loci (data not shown). In addition, a reduced signal intensity was observed for the shorter constitutional allele of the variable-number tandem repeat (VNTR) markers D2S44 and DIOS25 mapped to chromosomes 2 and 10, respectively, while the constitutional genotype was retained for markers on chromosomes 1, 5, and 22 (Table 2 ). These results indicate that allele losses on chromosome 11, and hence involving the MEN) locus, are relatively infrequent in sporadic adenomas of the anterior pituitary compared to sporadic parathyroid lesions.
The pituitary adenomas were also examined for allele losses on chromosomes 1, 2, 4, 5, 10, 13, 17, and 22. Of these adenomas, APA-32, which was an unusually aggressive tumor (Table 2) , showed multiple chromosome losses affecting chromosomes 1, 2, 4, 10, and 22 but retained constitutional heterozygosity on chromosome 11 atPYGMand INT2 (Table  2 ). In APA-11 and APA-28 single chromosome losses were found involving chromosomes 4 and 1, respectively, while both these lesions showed retained constitutional genotypes at all informative loci on chromosome 11 (Table 2 ).
Deletion Mapping in Tumors. The chromosome 11 deletions observed in HPT-9 and HPT-13 provided an approach for mapping of the MEN) region. These parathyroid lesions showed loss of alleles on part of chromosome 11 and retained the constitutional genotype for other regions of this chromosome. As shown in Fig. 1, HPT-9 showed loss of alleles for the llq markers D11S29, INT2, and DI1S146 but retained heterozygosity for PYGM. Unfortunately this individual was not informative for any of the markers examined on lip; therefore, the genotype was inferred from densitometeric determination of the signal intensity for homozygous loci. These analyses showed retained signal intensity in the tumor specimens for the PTH and INS loci on 11p15 (data not shown). The most likely chromosomal mechanism in HPT-9 is therefore a deletion (llql3-qter) with the breakpoint between PYGM and DIIS146.
The second case, HPT-13, showed retained genotype at DIIS29 and INT2 and loss of heterozygosity at PYGM (Fig.  1) . Allele losses on lip could not be determined in this case, due to the consistent constitutional homozygosity and the relatively limited amount of tissue available for examination. Densitometric examination, however, showed retained signal intensity for the PGA, CAT, D 1512, and PTH loci (data not shown). These markers are located from 11q13 to lipl5. In addition, D115146, which is 0.5 cM centromeric to INT2, showed reduced signal intensity. Although the exact nature of the chromosome mutation was to some extent inferred from densitometry in this case, these data indicate an interstitial deletion within 11q13 that eliminates the PYGM and D115146 loci but not the flanking INT2 and PGA loci.
A third MENi-associated lesion, an islet-cell tumor of case II-1 in the LU kindred, was previously studied in some detail and had shown loss of heterozygosity for all chromosome 11 markers analyzed (3). This analysis has been extended to identify homozygous loss of any marker within the MEN) region. Examination of this islet-cell tumor with the marker D11546 revealed retained constitutional heterozygosity, while the previously observed allele losses including PYGM were confirmed. These results indicate that this tumor has undergone a complex rearrangement with two breakpoints flanking the D11S146 locus and retaining this region. Together with previously published linkage data (4), the deletions in these three MENi-associated lesions indicate that the MEN] locus is close to and on the telomeric side of PYGM, centromeric to the DIIS146/INT2 region.
DISCUSSION
The association of neuroendocrine tumors ofdifferent origins in inherited syndromes suggests a common mechanism of pathogenesis and that the differentiation of these neoplastic parenchymal cells share common regulatory elements (16) . Experimental evidence for this hypothesis has been obtained from observations of gene deletions of a common region in several associated tumors such as retinoblastoma and osteosarcoma (6-9, 17), rhabdomyosarcoma, Wilms tumor and hepatoblastoma (18) (19) (20) (21) , and acoustic neurofibromatosis and meningioma (22) (23) (24) (25) . Furthermore, sporadic cases of these tumors show similar chromosome rearrangements affecting the same region to which the inherited form ofthe disease has INS 11-3 LU HPT been linked (6, 16, 17, 20, 21, 25 (4) ; the position of MEN) was established from the deletion data shown in Fig. 1. 6 , Recombination fraction.
The observation of relatively few allele losses on chromosome 11 in pituitary adenomas suggests a different pathogenesis in these lesions. At least two possibilities may explain this difference. Either the pathogenesis of sporadic pituitary adenomas involves mutational events of the MEN) locus, but predominantly a different genetic mechanism than that of the pancreatic and parathyroid lesions, or the pituitary lesions do not reflect mutational events of this gene. In the latter case, one may speculate that sporadic pituitary adenomas differ from MENi-associated lesions. Unfortunately, we have not been able to address this question, since MENi-associated pituitary adenomas are rarely subject to surgical therapy.
Finally, the relative difference in the frequency of gene deletions of the MEN] region in the parathyroid and pancreatic lesions on the one hand, and in the pituitary adenomas on the other, has implications for the strategy for cloning of the gene by the reversed genetic approach. Pancreatic islets and parathyroid glands would be expected to express this gene and hence be suitable for constructing cDNA libraries. The final identification of the disease gene will then depend on finding mutations and abnormal expression of the candidate gene in pancreatic and parathyroid lesions.
